Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ippei Shimizu

Showing results (71-80 of 72) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 72 results.
Life Science Alliance|July 24, 2020
BH4 activates CaMKK2 and rescues the cardiomyopathic phenotype in rodent models of diabetesHyoung Kyu Kim, Tae Hee Ko, In-Sung Song, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 24, 2020
Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and DesignShinya Fujiki, Kenichi Iijima, Masaaki Okabe, et al.
Pageof 8

Showing results (71-80 of 72) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 72 results.
Life Science Alliance|July 24, 2020
BH4 activates CaMKK2 and rescues the cardiomyopathic phenotype in rodent models of diabetesHyoung Kyu Kim, Tae Hee Ko, In-Sung Song, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 24, 2020
Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and DesignShinya Fujiki, Kenichi Iijima, Masaaki Okabe, et al.
Pageof 8